Clinical trial
A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)
NCT07613307 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 15, 2026
- Completion date
- May 31, 2027
- Enrollment
- 130 (estimated)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.
behavior, diabetes melletus, diabetes mellitus, type 2, endocrine system diseases, fasting, feeding behavior, glucagon-like peptide receptors, glucagon-like peptide-1 receptor, glucose metabolism disorders, membrane proteins, metabolic disorders, nutritional and metabolic diseases, proteins, receptors, cell surface, receptors, g-protein-coupled, receptors, peptide